DIN 02489597 — EVENITY 105 MG
EVENITY is a solution of Romosozumab marketed by AMGEN CANADA INC. The full Romosozumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02489597
- Brand name
- EVENITY
- Active ingredient
- Romosozumab
- Strength
- 105 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- AMGEN CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Sclerostin inhibitor (bone-formation agent)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.